Abstract
Ursodeoxycholic acid (UDCA) is a drug with multiple hepatoprotectant and anticholestatic properties. It is used extensively for the dissolution of gallstones and for the treatment of various cholestatic liver diseases. UDCA modifies the constituents of the bile acid pool, stimulates hepatobiliary secretion, exerts cytoprotective effects, inhibits bile acid absorption by cholangiocytes, and exerts immunomodulatory action. These cytoprotective effects alleviate hepatic inflammation and provide potential anti-fibrotic property of this compound. The mechanism involved in the direct inhibitory fibrogenetic effects is unclear, and the data concerning it is extremely limited. In clinical studies, UDCA has been shown to delay the progression of fibrosis, stabilize portal pressure, and delay development of varices and clinical decompensation in patients with primary biliary cholangitis. The effects of UDCA on liver fibrosis and cirrhosis in other chronic cholestatic disorders show heterogeneous results. In non-cholestatic disorders, UDCA demonstrated limited clinical benefits, and currently, there is insufficient evidence to support its use in these conditions. It should be emphasized that there is a possibility that the treatment duration in the studies may not be of sufficient length for the drug to show the effects, as the fibrosis may progress slowly. Future studies are required to elucidate long-term clinical benefits in conditions, such as cirrhosis, and also to investigate any potential cirrhosis-related complications.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Beuers U. Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol. 2006;3:318–28.
Paumgartner G, Beuers U. Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease. Clin Liver Dis. 2004;8:67–81, vi.
Angulo P. Use of ursodeoxycholic acid in patients with liver disease. Curr Gastroenterol Rep. 2002;4:37–44.
Perez MJ, Briz O. Bile-acid-induced cell injury and protection. World J Gastroenterol. 2009;15:1677–89.
Tang N, Zhang Y, Liang Q, Liu Z, Shi Y. The role of ursodeoxycholic acid on cholestatic hepatic fibrosis in infant rats. Mol Med Rep. 2018;17:3837–44.
Ye HL, Zhang JW, Chen XZ, Wu PB, Chen L, Zhang G. Ursodeoxycholic acid alleviates experimental liver fibrosis involving inhibition of autophagy. Life Sci. 2020;242:117175.
Zhang LX, Liang TJ, Tan YR, Ren WH, Han GQ, Zhang J, et al. Protective effects of ursodeoxycholic acid against immune-mediated liver fibrosis in rats. Hepato-Gastroenterology. 2010;57:1196–202.
Schiedermaier P, Hansen S, Asdonk D, Brensing K, Sauerbruch T. Effects of ursodeoxycholic acid on splanchnic and systemic hemodynamics. A double-blind, cross-over, placebo-controlled study in healthy volunteers. Digestion. 2000;61:107–12.
Berzigotti A, Bellot P, De Gottardi A, Garcia-Pagan JC, Gagnon C, Spenard J, et al. NCX-1000, a nitric oxide-releasing derivative of UDCA, does not decrease portal pressure in patients with cirrhosis: results of a randomized, double-blind, dose-escalating study. Am J Gastroenterol. 2010;105:1094–101.
Angulo P, Dickson ER, Therneau TM, Jorgensen RA, Smith C, DeSotel CK, et al. Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. J Hepatol. 1999;30:830–5.
Corpechot C, Carrat F, Bonnand AM, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology. 2000;32:1196–9.
Mayo MJ. Portal hypertension in primary biliary cirrhosis: a potentially reversible harbinger of demise. Gastroenterology. 2008;135:1450–1.
Huet PM, Vincent C, Deslaurier J, Cote J, Matsutami S, Boileau R, et al. Portal hypertension and primary biliary cirrhosis: effect of long-term ursodeoxycholic acid treatment. Gastroenterology. 2008;135:1552–60.
Lindor KD, Jorgensen RA, Therneau TM, Malinchoc M, Dickson ER. Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis. Mayo Clin Proc. 1997;72:1137–40.
Harms MH, de Veer RC, Lammers WJ, Corpechot C, Thorburn D, Janssen HLA, et al. Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis. Gut. 2020;69:1502–9.
Pinyopornpanish K, Chadalavada P, Talal Sarmini M, Khoudari G, Alomari M, Padbidri V, et al. Simplified 6-month prediction scores for primary biliary cholangitis patients treated with ursodeoxycholic acid. Eur J Gastroenterol Hepatol. 2022;34:411–6.
Chen S, Duan W, You H, Jia J. A brief review on prognostic models of primary biliary cholangitis. Hepatol Int. 2017;11:412–8.
Kumagi T, Guindi M, Fischer SE, Arenovich T, Abdalian R, Coltescu C, et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol. 2010;105:2186–94.
Ornolfsson KT, Lund SH, Olafsson S, Bergmann OM, Bjornsson ES. Biochemical response to ursodeoxycholic acid among PBC patients: a nationwide population-based study. Scand J Gastroenterol. 2019;54:609–16.
John BV, Khakoo NS, Schwartz KB, Aitchenson G, Levy C, Dahman B, et al. Ursodeoxycholic acid response is associated with reduced mortality in primary biliary cholangitis with compensated cirrhosis. Am J Gastroenterol. 2021;116:1913–23.
Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo primary Sclerosing cholangitis-Ursodeoxycholic acid study group. N Engl J Med. 1997;336:691–5.
Olsson R, Boberg KM, de Muckadell OS, Lindgren S, Hultcrantz R, Folvik G, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology. 2005;129:1464–72.
Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology. 2009;50:808–14.
Lindblad A, Glaumann H, Strandvik B. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease. Hepatology. 1998;27:166–74.
van der Feen C, van der Doef HP, van der Ent CK, Houwen RH. Ursodeoxycholic acid treatment is associated with improvement of liver stiffness in cystic fibrosis patients. J Cyst Fibros. 2016;15:834–8.
Toledano MB, Mukherjee SK, Howell J, Westaby D, Khan SA, Bilton D, et al. The emerging burden of liver disease in cystic fibrosis patients: a UK nationwide study. PLoS One. 2019;14:e0212779.
Boelle PY, Debray D, Guillot L, Clement A, Corvol H, French CFMGSI. Cystic fibrosis liver disease: outcomes and risk factors in a large cohort of French patients. Hepatology. 2019;69:1648–56.
Colombo C, Alicandro G, Oliver M, Lewindon PJ, Ramm GA, Ooi CY, et al. Ursodeoxycholic acid and liver disease associated with cystic fibrosis: a multicenter cohort study. J Cyst Fibros. 2022;21:220–6.
Jacquemin E, Hermans D, Myara A, Habes D, Debray D, Hadchouel M, et al. Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis. Hepatology. 1997;25:519–23.
Frider B, Castillo A, Gordo-Gilart R, Bruno A, Amante M, Alvarez L, et al. Reversal of advanced fibrosis after long-term ursodeoxycholic acid therapy in a patient with residual expression of MDR3. Ann Hepatol. 2015;14:745–51.
Pathil A, Mueller J, Warth A, Chamulitrat W, Stremmel W. Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease. Hepatology. 2012;55:1369–78.
Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology. 2004;39:770–8.
Leuschner UF, Lindenthal B, Herrmann G, Arnold JC, Rossle M, Cordes HJ, et al. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology. 2010;52:472–9.
Ratziu V, de Ledinghen V, Oberti F, Mathurin P, Wartelle-Bladou C, Renou C, et al. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol. 2011;54:1011–9.
Nakamura K, Yoneda M, Yokohama S, Tamori K, Sato Y, Aso K, et al. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol. 1998;13:490–5.
Czaja AJ, Carpenter HA, Lindor KD. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. Hepatology. 1999;30:1381–6.
Pelletier G, Roulot D, Davion T, Masliah C, Causse X, Oberti F, et al. A randomized controlled trial of ursodeoxycholic acid in patients with alcohol-induced cirrhosis and jaundice. Hepatology. 2003;37:887–92.
Fabbri C, Marchetto S, Pezzoli A, Accogli E, Fusaroli P, Azzaroli F, et al. Efficacy of ursodeoxycholic acid in association with alpha-interferon for chronic hepatitis C in alpha-interferon non-responder patients. Eur J Gastroenterol Hepatol. 2000;12:511–5.
Lirussi F, Beccarello A, Bortolato L, Morselli-Labate AM, Crovatto M, Ceselli S, et al. Long-term treatment of chronic hepatitis C with ursodeoxycholic acid: influence of HCV genotypes and severity of liver disease. Liver. 1999;19:381–8.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Pinyopornpanish, K. (2022). Ursodeoxycholic Acid in Liver Cirrhosis: An Evidence-Based Review. In: Qi, X., Yang, Y. (eds) Pharmacotherapy for Liver Cirrhosis and Its Complications. Springer, Singapore. https://doi.org/10.1007/978-981-19-2615-0_5
Download citation
DOI: https://doi.org/10.1007/978-981-19-2615-0_5
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-19-2614-3
Online ISBN: 978-981-19-2615-0
eBook Packages: MedicineMedicine (R0)